Sign up
EFTR

Effector Therapeutics Inc (NASDAQ: EFTR)

Healthcare · Biotechnology

$0.00

Last close · Nov 16, 2026 · NASDAQ USD

Set alert

The Quantellect read. The borrow fee is 5.16%. Descriptive summary of the data on this page, not a recommendation.

Relative valuationLower multiples than peers

P/S 69.6× vs peer median 13.9×

Momentum—

—

Trend—

—

Short interest—

FINRA settlement Oct 30, 2026

EFTR price chart

Price $0.00 · As of Nov 17, 2026, 8:44 PM ET

Open full chart →
Nov 16, 2026O $0.00H $0.00L $0.00C $0.00Vol 712

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First dateMay 18, 2026 ET
Last dateNov 16, 2026 ET
Open$0.00
High$0.00
Low$0.00
Close$0.00
Volume239,643
Plotted bars40

Plotted OHLCV bars

  1. May 18, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 9,987
  2. May 19, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 9,988
  3. May 20, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 9,987
  4. May 21, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 37,821
  5. May 27, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 685
  6. May 28, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 807
  7. May 29, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 3,523
  8. Jun 1, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 476
  9. Jun 3, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 500
  10. Jun 5, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 2,640
  11. Jun 8, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 978
  12. Jun 16, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 310
  13. Jun 17, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 251
  14. Jun 18, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 1,100
  15. Jun 26, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 17,971
  16. Jun 29, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 250
  17. Jul 6, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 1,000
  18. Jul 14, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 10,041
  19. Jul 15, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 3,610
  20. Jul 20, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 80
  21. Jul 22, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 165
  22. Jul 23, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 2,669
  23. Jul 24, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 264
  24. Jul 29, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 181
  25. Aug 13, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 186
  26. Aug 14, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 127
  27. Aug 18, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 225
  28. Aug 21, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 112,137
  29. Sep 1, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 378
  30. Sep 2, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 500
  31. Sep 16, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 100
  32. Sep 25, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 817
  33. Oct 1, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 5,903
  34. Oct 5, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 378
  35. Oct 6, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 1,700
  36. Oct 20, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 119
  37. Oct 22, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 500
  38. Oct 28, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 300
  39. Nov 5, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 277
  40. Nov 16, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 712

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of Nov 17, 2026, 8:44 PM ET

Initial 6M price range summary
Range6M
First close$0.00
Last close$0.00
High$0.00
Low$0.00
Volume239,643
Open
—Historical · Nov 16, 2026
Previous close
—Historical · Nov 16, 2026
Day range
—Historical · Nov 16, 2026
52-week range—
Volume
—Historical · Nov 16, 2026
Average volume (30 calendar days)—
Market cap—
P/E (TTM)—
Forward P/E—
EPS (TTM)—
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

EFTR · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

Sessions where the close moved at least twice its average daily move of the prior 20 sessions (minimum 3%), or 10% or more.

  1. $0.00−75.00%

    Trading volume was 2.4 times the 30-day average, with 712 shares traded.

  2. $0.00+300.00%

    Trading volume was 0.4 times the 30-day average, with 277 shares traded.

  3. $0.00−75.00%

    Trading volume was 0.2 times the 30-day average, with 300 shares traded.

Options flow

— · Options flow not available

Q Score

—/100—

Latest available: Nov 13, 2026 · updates irregularly

Each axis is a 0 to 100 percentile rank among equities

Not scored: Equity peers

LiquidityNot scoredShortNot scoredSqueezeNot scoredTrendNot scoredMomentumNot scoredValuationNot scoredStabilityNot scored
What each one means
  • LiquidityNot scored

    Higher scores reflect greater average dollar trading volume and less absolute return per dollar traded over 21 sessions within equity peers.

  • ShortNot scored

    Higher scores reflect less short-interest pressure relative to trading volume and the company's own history, and less growth in shares short, within equity peers.

  • SqueezeNot scored

    Higher scores reflect a higher published Squeeze score within equity peers.

  • TrendNot scored

    Higher scores reflect a price nearer its 252-session split-adjusted closing high and positive 63- and 126-session total returns.

  • MomentumNot scored

    Higher scores reflect stronger 63- and 126-session total returns within equity peers.

  • ValuationNot scored

    Higher scores reflect lower positive P/E, P/B, EV/EBITDA and price/sales multiples within equity peers; limited data pulls the score toward neutral.

  • StabilityNot scored

    Higher scores reflect lower daily total-return volatility over 63 and 252 sessions within equity peers.

How the Q Score works →

Quantellect signals

Change since Nov 17

Insufficient data · Tide session Nov 17, 2026

Tide46Calm Tide—
Squeeze46Watch—
How the scores work →

How EFTR compares with its industry

Against 592 other US-listed Biotechnology stocks

Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%

Strongest points

  1. Latest-quarter year-over-year sales growth was 117%, higher than 89% of 592 peers.Peer median 0.0% · As of Nov 17, 2026
  2. Three-month return was 0%, higher than 86% of 559 peers.Peer median −31.7% · As of Nov 15, 2026

Points of caution

  1. Trailing-year return on equity was -946.6%, with only 1% of 554 peers reporting a lower value.Peer median −67.8% · As of Nov 17, 2026
  2. One-month return was -66.7%, with only 3% of 567 peers reporting a lower value.Peer median −10.3% · As of Nov 15, 2026
  3. Trailing-year net margin was 0%, with only 19% of 583 peers reporting a lower value.Peer median 0.0% · As of Nov 17, 2026

Valuation

Lower multiples than peers

  • Price/sales69.65×13.85×

    Higher than 75% of 407 peers

  • Forward P/E—14.90×

    Not ranked: only 194 of 592 peers report it

  • Price/book0.00×2.58×
    Lowest of 551 peers

    Higher than 0% of 551 peers

Profitability

Profitability metrics are lower than most peers.

  • Gross margin—78.4%

    Not ranked: only 247 of 592 peers report it

  • Operating margin0.0%0.0%

    Higher than 26% of 442 peers

  • Net margin0.0%0.0%

    Higher than 19% of 583 peers

  • Return on equity−946.6%−67.8%
    Bottom 10% of peers

    Higher than 1% of 554 peers

Growth

Growth metrics are higher than most peers.

  • Quarterly sales growth, year over year117.0%0.0%

    Higher than 89% of 592 peers

  • 5-year sales growth rate—11.3%

    Not ranked: only 140 of 592 peers report it

Balance sheet

Not enough peers report balance sheet metrics for a group comparison.

  • Current ratio—5.01

    Not ranked: only 499 of 592 peers report it

  • Debt/equity (total borrowings)—0.23

    Not ranked: only 117 of 592 peers report it

Momentum

Returns are higher than most peers.

  • 1-year return—−29.8%

    Not ranked: only 523 of 592 peers report it

  • 6-month return—−24.0%

    Not ranked: only 548 of 592 peers report it

  • 3-month return0.0%−31.7%

    Higher than 86% of 559 peers

Compared with 592 other US-listed Biotechnology stocks · fundamentals as of Nov 1, 2026 · prices as of Nov 12, 2026

Upcoming events

— · Upcoming events not available

Analyst consensus

— · Analyst consensus not available

Earnings history

— · Earnings history not available

Smart-money activity

In the last 60 days: 0 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.

DateTypeWhoActionAmountSource
13FTWO SIGMA INVESTMENTS, LPClosed position$013F filing
13FTWO SIGMA INVESTMENTS, LPOpened position$3.2K13F filing
Insider sellSR ONE CAPITAL MANAGEMENT, LLC / SR One Capital Fund I Aggregator LP / SR ONE CAPITAL PARTNERS I, LP / SR One Co-Invest I, LLC / SR One Co-Invest I Manager, LLC / George SimeonSell$108.3KForm 4
Insider sellSR ONE CAPITAL MANAGEMENT, LLC / SR One Capital Fund I Aggregator LP / SR ONE CAPITAL PARTNERS I, LP / SR One Co-Invest I, LLC / SR One Co-Invest I Manager, LLC / George SimeonSell$261.1KForm 4
Insider buyEhrlich Christopher BBuy$197Form 4
Insider buyEhrlich Christopher BBuy$10.4KForm 4
Insider sellPresidio Management Group X LLC / US VENTURE PARTNERS X LP / USVP X AFFILIATES LP / Tansey Casey M / ROOT JONATHAN DSell$1.4KForm 4
Insider sellPresidio Management Group X LLC / US VENTURE PARTNERS X LP / USVP X AFFILIATES LP / Tansey Casey M / ROOT JONATHAN DSell$46.3KForm 4
Insider sellPresidio Management Group X LLC / US VENTURE PARTNERS X LP / USVP X AFFILIATES LP / Tansey Casey M / ROOT JONATHAN DSell$680Form 4
Insider sellPresidio Management Group X LLC / US VENTURE PARTNERS X LP / USVP X AFFILIATES LP / Tansey Casey M / ROOT JONATHAN DSell$21.8KForm 4
All smart-money activity →

News and press releases

News and press releases are not available.

All EFTR news →

Company profile

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. It also develops Tomivosertib, an oral

CEO
—
Headquarters
Solana Beach, CA, United States
Employees
14
IPO date
Aug 26, 2021
Sector
Healthcare
Industry
Biotechnology

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.